Scientific programme

The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world’s top specialists. It also includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines.  The focus of all sessions is clinical practice founded on science, with practical messages to take home.
Scientific sessions are held from Thursday, March 17 to Saturday, March 19, 2016. No parallel sessions are scheduled. The congress registration fee includes access to all scientific sessions.

Preliminary programme
(as of June 2015)

IBD innovations driving clinical decisions

  • Plenary hall

      10:45-11:15 Top tips for chairs (Closed session)
    Laurence Egan, Galway, Ireland
    11:30-12:30
    Industry sponsored satellite symposia 1a & 1b 
      12:45-12:50 Welcome
    Janneke van der Woude, Rotterdam, The Netherlands
    Bas Oldenburg, Utrecht, The Netherlands
      12:50-13:00 Opening
    Séverine Vermeire, Leuven, Belgium
    13:00-14:30 
    Scientific session 1: Cell therapy: Ready for cinical practice?
    Pierre Desreumaux, Lille, France
    Dominik Bettenworth, Muenster, Germany
      13:00-13:20 Haematopoietic stem cell transplantation
    Azucena Salas, Barcelona, Spain (basic)
    Elena Ricart, Barcelona, Spain (clinical)
      13:20-13:30 Best abstract: A phase III randomised controlled trial of Cx601,
    expanded allogeneic adipose-derived mesenchymal stem cells
    (eASC), for complex perianal fistulae in Crohn’s Disease
    J. Panés1, D. García-Olmo2, G. van Assche3, J.F. Colombel4, W.
    Reinisch5, D.C. Baumgart6, M. Nachury7, M. Ferrante3, L. Kazemi-
    Shirazi5, J.C. Grimaud8, F. de la Portilla9, E. Goldin10, A. Leselbaum11,
    M.C. Diez11, S. Danese12
    1Hospital Clínic Barcelona, Barcelona, Spain, 2Hospital U. Fundación
    Jiménez-Díaz, Madrid, Spain, 3University Hospitals Leuven, KU
    Leuven, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai,
    New York, United States, 5Medical University of Vienna, Vienna,
    Austria, 6Charité Medical School - Humboldt-University of Berlin,
    Berlin, Germany, 7CHU Lille, Lille, France, 8Hôpital Nord, Marseille,
    France, 9Hospital Virgen del Rocío, Sevilla, Spain, 10Sharee Zedek
    MC, Jerusalem, Israel, 11TiGenix, Madrid, Spain, 12Istituto Clinico
    Humanitas, Milano, Italy
      13:30-13:50 Immune cell manipulation
    Graham Lord, London, United Kingdom (basic)
    Matthieu Allez, Paris, France (clinical)
      13:50-14:00 Best abstract: Histopathological response and remission
    after dual topical application of the toll-like-receptor 9 agonist
    DIMS0150 in patients with moderate to severe Ulcerative Colitis
    R. Atreya
    1, A. Öst2, C. Admyre3, A. Karlsson3, T. Knittel3, J. Kowalski3, F.
    Scaldaferri4, M. Neurath1, C. Hawkey5
    1University of Erlangen-Nuernberg, Department of Medicine 1,
    Erlangen, Germany, 2Aleris Medilab, Department of Pathology
    and Cytology, Täby, Sweden, 3Index Pharmaceuticals, Stockholm,
    Sweden, 4Catholic University of Rome, Internal Medicine
    Department, Gastroenterology Division, Rome, Italy, 5Nottingham
    University Hospitals, Department of Gastroenterology, Nottingham,
    United Kingdom
      14:00-14:20 Mesenchymal stem cells
    Stefania Vetrano, Milan, Italy
    Laurence Egan, Galway, Ireland
      14:20-14:30 Best abstract: Predicting short and medium-term efficacy of the
    biosimilar infliximab: Trough levels/ADAs or clinical/biochemical
    markers play a more important role?
    P.A. Golovics
    1, Z. Vegh1, M. Rutka2, K. Gecse1, A. Balint2, K. Farkas2, J.
    Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K.
    Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, G.T. Toth13, A.
    Vincze14, E. Biro15, B. Lovasz1, Z. Kurti1, F. Nagy12, T. Molnar2, P. Lakatos1
    1Semmelweis University, 1st Department of Medicine, Budapest,
    Hungary, 2University of Szeged, 1st Department of Medicine, Szeged,
    Hungary, 3Military Hospital, State Health Centre, Department
    of Gastroenterology, Budapest, Hungary, 4Peterfy Hospital, 1st
    Department of Medicine, Budapest, Hungary, 5Zala County Hospital,
    2nd Department of Medicine, Zalaegerszeg, Hungary, 6B-A-Z County
    and University Teaching Hospital, 2nd Department of Medicine,
    Miskolc, Hungary, 7Csolnoky F. Province Hospital, Department
    of Medicine, Veszprem, Hungary, 8Semmelweis University, 2nd
    Department of Medicine, Budapest, Hungary, 9University of
    Debrecen, Institute of Medicine, Department of Gastroenterology,
    Debrecen, Hungary, 10Markusovszky Hospital, 1st Department of
    Medicine and Gastroenterology, Szombathely, Hungary, 11Tolna
    County Teaching Hospital, 1st Department of Gastroenterology,
    Szekszard, Hungary, 12University of Szeged, First Department of
    Internal Medicine, Szeged, Hungary, 13Janos Hospital, Department
    of Gastroenterology, Budapest, Hungary, 14University of Pecs, 1st
    Department of Medicine, Pecs, Hungary, 15Semmelweis University,
    Department of Laboratory Medicine, Budapest, Hungary
    14:30-15:00 Coffee break 
    15:00-17:00 Scientific session 2: Application of genetic testing in understanding and managing IBD
    Andre Franke, Kiel, Germany
    Thomas Billiet, Heverlee, Belgium
      15:00-15:20 Very early onset IBD - from research to bedside
    Holm Uhlig, Oxford, United Kingdom
      15:20-15:30 Best abstract: Gene expression profiling indicates similar
    molecular pathways are active in adult and paediatric Crohn’s
    Disease
    A. Stojmirovic, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman
    Janssen R & D, LLC, Spring House, United States
      15:30-15:50 Genetics in predicting drug response
    Tariq Ahmad, Exeter, United Kingdom
      15:50-16:00 Best abstract: A variable number of tandem repeat
    polymorphism in the promotor region of the neonatal Fc receptor
    affects anti-TNF serum levels in IBD
    T. Billiet
    1, I. Cleynen1, M. Ferrante2, G. van Assche2, A. Gils3, S.
    Vermeire2
    1Department of Clinical and Experimental Medicine, KU Leuven,
    Translational Research in GastroIntestinal Disorders (TARGID),
    Leuven, Belgium, 2University Hospitals Leuven, Gastroenterology
    - Translational Research Center for Gastrointestinal Disorders
    (TARGID), Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic
    and Diagnostic Antibodies, Leuven, Belgium
      16:00-16:10 Best abstract: Autophagy regulates dendritic cell migration
    through Rac1 – implications for thiopurine therapy
    M. Wildenberg
    1, P. Koelink2, K. Diederen2, A. te Velde2, V. Nuij3, M.
    Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude3, G.
    D‘Haens1, G. van den Brink1
    1Academic Medical Center, Gastroenterology and Hepatology,
    Amsterdam, Netherlands, 2Academic Medical Center, Tytgat Institute,
    Amsterdam, Netherlands, 3Erasmus Medical Center, Department
    of Gastroenterology and Hepatology, Rotterdam, Netherlands,
    4Beatson Institute for Cancer Research, Glasgow, United Kingdom
      16:10-16:30 The future of genetics in clinical medicine
    Rinse Weersma, Groningen, The Netherlands
      16:30-16:40 Best abstract: Comprehensive epigenome-wide DNA
    methylation profiling in Inflammatory Bowel Disease
    N. Ventham
    1, N. Kennedy1, A. Adams1, R. Kalla1, S. Heath2, K. O‘Leary1,
    H. Drummond1, D. Wilson3, on behalf of the IBD-BIOM Consortium1,
    on behalf of the IBD-CHARACTER Consortium1, I. Gut2, E.R. Nimmo1,
    J. Satsangi1
    1University of Edinburgh, CGEM, Edinburgh, United Kingdom,
    2Centro Nacional de Análisis Genómico, Barcelona, Spain, 3University
    Of Edinburgh, Department of Child Life and Health, Edinburgh,
    United Kingdom
      16:40-16:50 Best abstract: Genotype-phenotype analysis across 130,422
    genetic variants identifies RSPO3 as the first genome-wide
    significant modifier gene in primary sclerosing cholangitis
    R. Alberts
    1, E.M. de Vries2, G. Alexander3, D. Alvaro4, A. Bergquist5, U.
    Beuers2, E. Björnsson6, K.M. Boberg7, C.L. Bowlus8, R.W. Chapman9, O.
    Chazouillères10, A. Cheung11, G. Dalekos12, B. Eksteen13, D. Ellinghaus14,
    M. Färkkilä15, E.A. Festen1, A. Floreani16, T. Folseraas7, E. Goode17,
    D.N. Gotthardt18, G.M. Hirschfield19, B. van Hoek20, K. Holm7, S.
    Hohenester21, J.R. Hov7, F. Imhann1, P. Invernizzi22, X. Jiang7, J. Eaton23,
    B.D. Juran24, K.N. Lazaridis24, V. Leppa25, J.Z. Liu26, J. Löfberg27, M.P.
    Manns28, H.-U. Marschall29, M. Marzioni30, A.L. Mason31, E. Melum7,
    P. Milkiewicz32, T. Müller33, A. Pares34, C. Rupp35, S.M. Rushbrook36, C.
    Rust37, F. Sampaziotis38, R.N. Sandford39, C. Schramm40, S. Schreiber14,
    E. Schrumpf7, M. Silverberg41, B. Srivastava39, M. Sterneck42, A. Teufel43,
    L. Tittmann44, L. Vallier38, A.V. Vila1, B. de Vries1, T.J. Weismüller28, C.
    Wijmenga45, K. Zachou46, A. Franke14, C.A. Anderson26, T.H. Karlsen7,
    C.Y. Ponsioen2, R.K. Weersma1
    1University of Groningen and University Medical Centre
    Groningen, Department of Gastroenterology and Hepatology,
    Groningen, Netherlands, 2Academic Medical Center, Department
    of Gastroenterology and Hepatology, Amsterdam, Netherlands,
    3University of Cambridge, Department of Medicine, Division
    of Hepatology, Cambridge, United Kingdom, 4Sapienza
    University of Rome, Department of Clinical Medicine, Division
    of Gastroenterology, Rome, Italy, 5Karolinska University Hospital
    Huddinge, Karolinska Institutet, Department of Gastroenterology
    and Hepatology, Stockholm, Sweden, 6Landspitali University
    Hospital, Department of Internal Medicine, Division of
    Gastroenterology and Hepatology, Reykjavik, Iceland, 7Oslo
    University Hospital, Rikshospitalet, Norwegian PSC Research Center,
    Division of Cancer Medicine, Surgery and Transplantation, Oslo,
    Norway, 8University of California Davis, Division of Gastroenterology
    and Hepatology, Davis, United States, 9John Radcliffe University
    Hospitals NHS Trust, Department of Hepatology, Oxford, United
    Kingdom, 10Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, APHP
    and Department of Hepatology, Paris, France, 11University
    Health Network - Toronto General Hospital, Gen. Internal Medicine,
    Toronto, Canada, 12Medical School, University of Thessaly,
    Department of Medicine and Research Laboratory of Internal
    Medicine, Larissa, Greece, 13University of Calgary, Snyder Institute
    of Chronic Diseases, Department of Medicine, Calgary, Canada,
    14Christian-Albrechts-University of Kiel, Institute of Clinical Molecular
    Biology, Kiel, Germany, 15Helsinki University Hospital, Division of
    Gastroenterology, Department of Medicine, Helsinki, Finland,
    16University of Padova, Department of Surgical, Oncological and
    Gastroenterological Sciences, Padova, Italy, 17Norfolk and Norwich
    University Hospital, Department of Gastroenterology, Norwich,
    United Kingdom, 18University Hospital of Heidelberg, Department
    of Medicine, Heidelberg, Germany, 19University of Toronto, Division
    of Gastroenterology, Department of Medicine, Toronto, Canada,
    20Leiden University Medical Centre, Department of Gastroenterology
    and Hepatology, Leiden, Netherlands, 21University of Munich,
    Department of Medicine II, Munich, Germany, 22Humanitas Clinical
    and Research Center, Center for Autoimmune Liver Diseases,
    Rozzano, Italy, 23Mayo Clinic, Division of Gastroenterology and
    Hepatology, Rochester, United States, 24Mayo Clinic, College of
    Medicine, Center for Basic Research in Digestive Diseases, Division of
    Gastroenterology and Hepatology, Rochester, United States, 25Institute for Molecular Medicine Finland F.I.M.M., University of
    Helsinki and National Institute for Health and Welfare, Public Health
    Genomics Unit, Helsinki, Finland, 26Wellcome Trust Sanger Institute,
    Wellcome Trust Genome Campus, Hinxton, Cambridge, United
    Kingdom, 27Karolinska Institute, Stockholm, Sweden, 28Hannover
    Medical School, Department of Gastroenterology, Hepatology
    and Endocrinology, Hannover, Germany, 29Institute of Medicine,
    Sahlgrenska Academy and University Hospital, Department of
    Internal Medicine, Gothenburg, Sweden, 30Università Politecnica
    delle Marche, Ospedali Riuniti University Hospital, Department of
    Gastroenterology, Ancona, Italy, 31University of Alberta, Division of
    Gastroenterology and Hepatology, Edmonton, Canada, 32Medical
    University of Warsaw, Liver and Internal Medicine Unit, Warsaw,
    Poland, 33Charité Universitätsmedizin Berlin, Department of Internal
    Medicine, Hepatology and Gastroenterology, Berlin, Germany,
    34University of Barcelona, Liver Unit, Hospital Clínic, I.D.I.B.A.P.S.,
    C.I.B.E.R.ehd, Barcelona, Spain, 35University Hospital of Heidelberg,
    Department of Internal Medicine IV, Heidelberg, Germany,
    36University Hospitals NHS Trust, Department of Gastroenterology
    and Hepatology, Norfolk and Norwich, Norwich, United Kingdom,
    37University of Munich, Department of Medicine 2, Grosshadern,
    Munich, Germany, 38Wellcome Trust-Medical Research Council
    Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United
    Kingdom, 39University of Cambridge, Academic Department of
    Medical Genetics, Cambridge, United Kingdom, 40University Medical
    Center Hamburg-Eppendorf, 1st Department of Medicine, Hamburg,
    Germany, 41Mount Sinai Hospital Toronto, Inflammatory Bowel
    Disease (IBD) Group, Zane Cohen Centre for Digestive Diseases,
    Toronto, Canada, 42University Medical Center Hamburg-Eppendorf,
    Department of Hepatobiliary Surgery and Transplantation, Hamburg,
    Germany, 43University of Mainz, 1st Department of Medicine,
    Mainz, Germany, 44Christian-Albrechts-University of Kiel, Institute
    for Epidemiology, Kiel, Germany, 45University of Groningen and
    University Medical Centre Groningen, Department of Genetics,
    Groningen, Netherlands, 46University of Thessaly, Department of
    Internal Medicine, Larissa, Greece
      16:50-17:00 Best abstract: Gene-microbiome interactions underlying the
    onset and the clinical phenotypes of Inflammatory Bowel Disease
    F. Imhann
    1, A. Vich Vila1, M.J. Bonder2, D. Gevers3, J. Fu2, M.C.
    Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R.W.F.
    Ter Steege1, C. Huttenhower4, G. Dijkstra1, R.J. Xavier3, C. Wijmenga2,
    E.A.M. Festen1, A. Zhernakova2, R.K. Weersma1
    1University of Groningen and University Medical Center Groningen,
    Department of Gastroenterology and Hepatology, Groningen,
    Netherlands, 2University of Groningen and University Medical Center
    Groningen, Department of Genetics, Groningen, Netherlands,
    3The Broad Institute of MIT and Harvard, Cambridge, United States,
    4Harvard School of Public Health, Biostatistics Department, Boston,
    United States
    17:15-18:15
    Industry sponsored satellite symposia 2a & 2b 
    17:15-18:15 Digital oral presentations (Sessions 1-5)
  • Plenary hall

    07:15-08:15              Industry sponsored satellite symposia 3a & 3b
    08:30-09:30 Scientific session 3: Resolution of inflammation
    Javier Gisbert, Madrid, Spain
    Giovanni Monteleone, Rome, Italy
      08:30-08:50              Mechanisms by which inflammation resolves
    Silvio Danese, Milan, Italy
      08:50-09:10 Stopping drugs
    Charlie Lees, Edinburgh, United Kingdom
      09:10-09:20 Best abstract: Azathioprine dose reduction in Inflammatory
    Bowel Disease patients on combination therapy: A prospective
    study
    E. Del Tedesco1, S. Paul2, H. Marotte3, C. Jarlot1, N. Williet4, J.M. Phelip4,
    L. Peyrin-Biroulet5, J.F. Colombel6, X. Roblin4
    1University Hospital, Gastroenterology, Saint Etienne, France,
    2University of Saint Etienne, Immunology, Saint Etienne, France,
    3University Hospital, Rheumatology, Saint Etienne, France, 4CHU
    Saint Etienne, Saint Etienne, France, 5CHU de Nancy, Department
    of Gastroenterology, Vandoeuvre-Lès-Nancy, France, 6Mount Sinai
    Hospital, New York, United States
      09:20-09:30 Best abstract: Comparison of adalimumab monotherapy
    and a combination with azathioprine for patients with Crohn’s
    Disease: A prospective, multicentre, open-labeled clinical trial
    (DIAMOND study)
    T. Matsumoto
    1, S. Motoya2, K. Watanabe3, T. Hisamatsu4, H. Nakase5,
    N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M.
    Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M.
    Watanabe11, T. Hibi17
    1Iwate Medical University, Division of Gastroenterology, Department
    of Medicine, Morioka, Japan, 2Sapporo Kosei General Hospital,
    Inflammatory Bowel Disease Center, Sapporo, Japan, 3Osaka City
    General Hospital, Division of Gastroenterology, Osaka, Japan,
    4Kyorin University School of Medicine, The Third Department of
    Internal Medicine, Tokyo, Japan, 5Kyoto University, Department of
    Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto,
    Japan, 6Tokyo Yamate Medical Center, Department of Medicine,
    Division of Gastroenterology, Tokyo, Japan, 7Oita Red Cross Hospital,
    Department of Gastroenterology, Oita, Japan, 8Saitama Medical
    Center, Saitama Medical University, Department of Gastroenterology
    and Hepatology, Kawagoe, Japan, 9Chiba University, Department
    of Gastroenterology and Nephrology (K1), Graduate School of
    Medicine, Chiba, Japan, 10Kyushu University, Department of
    Medicine and Clinical Science, Graduate School of Medical Sciences,
    Fukuoka, Japan, 11Tokyo Medical and Dental University, Department
    of Gastroenterology and Hepatology, Tokyo, Japan, 12Fukuoka
    University Chikushi Hospital, Department of Gastroenterology,
    Chikushino, Japan, 13Kyoto Prefectural University of Medicine,
    Graduate School of Medical Science, Department of Molecular
    Gastroenterology and Hepatology, Kyoto, Japan, 14Keio University,
    Department of Internal Medicine, School of Medicine, Tokyo, Japan,
    15Toho University Sakura Medical Center, Department of Internal
    Medicine, Sakura, Japan, 16The Institute of Medical Science Hospital,
    The University of Tokyo, Center for Translational Research, Tokyo,
    Japan, 17Kitasato University Kitasato Institute Hospital, Center for
    Advanced IBD Research and Treatment, Tokyo, Japan
    09:30-10:30 Scientific session 4: Viruses and IBD
    Laurent Beaugerie, Paris, France
    Marina Shapina, Moscow, Russia
      09:30-09:50 Should we treat CMV in patients with UC?
    Britta Siegmund, Berlin, Germany
      09:50-10:00 Best abstract: Risk factors for colorectal neoplasia in
    Ulcerative Colitis: Results from the largest and longest-running
    colonoscopic surveillance programme
    C.H.R. Choi
    1,2, I. Al Bakir1,2, N.S.J. Ding1, M. Moorghen1, S. Thomas-
    Gibson1, J. Warusavitarne1, B. Saunders1, M. Rutter3, T. Graham2, A.
    Hart1
    1St. Mark‘s Hospital, London, United Kingdom, 2Barts Cancer Institute,
    Tumour Biology, London, United Kingdom, 3University Hospital of
    North Tees, Department of Gastroenterology, Stockton-on-Tees,
    Teesside, United Kingdom
      10:00-10:10 Best abstract: Evolution of corticosteroid use in Crohn’s
    Disease patients between 1991 and 2014: Results from the Dutch
    population-based IBDSL cohort
    S. Jeuring
    1, 2, V. Biemans1, L. Liu1, T. van den Heuvel1, 2, M. Zeegers3, 4,
    W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1,
    2, D. Jonkers1, 2, M. Pierik1, 2
    1Maastricht University Medical Centre, Internal Medicine - Division
    of Gastroenterology and Hepatology, Maastricht, Netherlands,
    2Maastricht University Medical Centre, NUTRIM - School for
    Nutrition and Translational Research in Metabolism, Maastricht,
    Netherlands, 3Maastricht University Medical Centre, Complex
    Genetics - School for Nutrition and Translational Research in
    Metabolism (NUTRIM), Maastricht, Netherlands, 4Maastricht
    University Medical Centre, CAPHRI - School for Public Health and
    Primary Care, Maastricht, Netherlands, 5Zuyderland Medical Centre,
    Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen,
    Netherlands, 6Zuyderland Medical Centre, Internal Medicine and
    Gastroenterology-Hepatology, Heerlen, Netherlands
      10:10-10:30 Other viral complications in clinical practice
    Jonas Halfvarson, Örebrö, Sweden
    10:30-11:00 Coffee break
    11:00-12:20 Scientific session 5: Challenging dogmas - from clinical trials to clinical practice
    Torsten Kucharzik, Lüneburg, Germany
    Maria Chaparro, Madrid, Spain
      11:00-11:20 Mucosal healing - Is it the holy grail?
    Geert D'Haens, Amsterdam, The Netherlands
      11:20-11:30 Best abstract: A multicentre, double-blind, placebo-controlled
    phase3 study of ustekinumab, a human interleukins-12/23p40
    mab, in moderate-severe Crohn’s Disease refracto-ry to anti-TNFα:
    UNITI-1
    P. Rutgeerts
    1, C. Gasink2, M. Blank3, Y. Lang2, J. Johanns2, L.-L. Gao2, B.
    Sands4, S. Hanauer5, B. Feagan6, S. Targan7, S. Ghosh8, W. de Villiers9,
    J.-F. Colombel10, S. Lee11, P. Desreumaux12, E.V. Loftus Jr13, S. Vermeire14, W.J. Sandborn15
    1University Hospital Gasthuisberg, Department of Haematology,
    Leuven, Netherlands, 2Janssen R & D, LLC, Spring House, United
    States, 3Janssen Scientific Affairs, LLC., Horsham, United States,
    4Mount Sinai Medical Center, New York, United States, 5Northwestern
    University Feinberg School of Medicine, Chicago, United States,
    6Robarts Clinical Trials, Robarts Research Institute, Western
    University, London, Canada, 7Cedars-Sinai Medical Center, Division of
    Gastroenterology, Los Angeles, United States, 8University of Calgary,
    Department of Gastroenterology, Calgary, Canada, 9Universiteit
    Stellenbosch University, Stellenbosch, South Africa, 10Mount Sinai,
    Icahn School of Medicine, New York, United States, 11University
    of Washington, Seattle, United States, 12University of Lille, Lille,
    France, 13Mayo Clinic Rochester, Depart-ment of Gastroenterology,
    Rochester, United States, 14University Hospitals Leuven, Department
    of Gastroenterology, Leuven, Belgium, 15University of California San
    Diego, Division of Gastroenterology, La Jolla, United States
      11:30-11:40 Best abstract: Results of ANDANTE, a randomised clinical
    study with an anti-IL6 antibody (PF-04236921) in subjects with
    Crohn’s Disease who are anti-TNF inadequate responders
    S. Danese
    1, S. Vermeire2, P. Hellstern3, R. Panaccione4, G. Rogler5,
    G. Fraser6, A. Kohn7, P. Desreumaux8, R.W. Leong9, G.M. Comer10, F.
    Cataldi10, A. Banerjee10, M.K. Maguire11, C. Li10, N. Rath11, J. Beebe10, S.
    Schreiber12
    1Humanitas University Clinical and Research Hospital, Rozzano,
    Milan, Italy, 2University Hospitals Leuven, Leuven, Belgium, 3Nature
    Coast Clinical Research, Inverness, United States, 4University of
    Calgary, Calgary, Canada, 5University of Zürich, Zürich, Switzerland,
    6Rabin Medical Centre and University of Tel-Aviv, Petah Tikva,
    Israel, 7AO San Camillo Forlanini, Rome, Italy, 8University of Lille,
    Inserm U995, Lille, France, 9Concord Hospital, Sydney, New South
    Wales, Australia, 10Pfizer Inc, Cambridge, United States, 11Pfizer Inc,
    Collegeville, United States, 12Christian-Albrechts University, Kiel,
    Germany
      11:40-12:00 Patient-reported outcomes
    William Sandborn, San Diego, United States
      12:00-12:20 Should clinical trials in children be different?
    Dan Turner, Jerusalem, Israel
    12:20-13:20 Lunch break
    Guided poster session
    12:30-13:10
    Industry sponsored educational lunchtime satellite symposia LS1, LS2, LS3, LS4 
    13:20-14:50 Scientific session 6: Bugs and drugs in IBD
    Philippe Seksik, Paris, France
    Barry Hall, Dublin, Ireland
      13:20-13:40 The microbiome and geographical spread of IBD
    Philip Rosenstiel, Kiel, Germany
      13:40-13:50 Best abstract: Development and validation of diagnostic
    criteria for IBD-Unclassified (IBDU) in children: A multicentre
    longitudinal study from the Paediatric IBD Porto group of
    ESPGHAN

    L. Birimberg Schwartz1, D. Zucker2, A. Akriv2, C. Salvatore3, F.
    Cameron4, I. Lazowska5, L. Yianni6, P. Siba7, S. Kolacek8, C. Romano9, S. Buderus10, A. Pærregaard11, J. C. Escher12, D. Turner13
    1Shaare Zedek Medical Center, Paediatrics, Jerusalem, Israel, 2The
    Hebrew University, Jerusalem, Israel, 3Sapienza University of
    Rome, Rome, Italy, 4Yorkhill Children’s Hospital, Glasgow, United
    Kingdom, 5Medical University of Warsaw, Warsaw, Poland, 6University
    Hospital Southampton, Hampshire, United Kingdom, 7University
    of Dundee, Scotland, United Kingdom, 8Zagreb University Medical
    School, Zagreb, Croatia, 9University of Messina, Messina, Italy, 10St.
    Marien Hospital, Bonn, Germany, 11Hvidovre University Hospital,
    Copenhagen, Denmark, 12Erasmus Medical Center, Netherlands,
    13Shaare Zedek Medical Center, Jerusalem, Israel
      13:50-14:10 Manipulating the microbiota in everyday practice
    Francisco Guarner, Barcelona, Spain
      14:10-14:20 Best abstract: Multi donor intense faecal microbiota
    transplantation is an effective treatment for resistant Ulcerative
    Colitis: A randomised placebo-controlled trial

    S. Paramsothy1, M. Kamm2,3, A. Walsh4, J. van den Bogaerde5, D.
    Samuel6, R. Leong6, S. Connor7, W. Ng7, R. Paramsothy7, N. Kaakoush8,
    H. Mitchell8, W. Xuan9, E. Lin10, T. Borody10
    1University of New South Wales, St Vincent‘s Clinical School, Sydney,
    Australia, 2St Vincent‘s Hospital, Melbourne, Australia, 3Imperial
    College London, London, United Kingdom, 4St Vincent‘s Hospital,
    Sydney, Australia, 5Nambour General Hospital, Nambour, Australia,
    6Bankstown-Lidcombe Hospital, Sydney, Australia, 7Liverpool
    Hospital, Sydney, Australia, 8University of New South Wales, School of
    Biotechnology & Biomolecular Sciences, Sydney, Australia, 9Ingham
    Institute, Sydney, Australia, 10Centre for Digestive Diseases, Sydney,
    Australia
      14:20-14:30 Best abstract: The impact of “Crohn’s Disease-TReatmentwith-
    EATing“ diet (CD-TREAT diet) and exclusive enteral nutrition
    on healthy gut bacteria metabolism

    V. Svolos1, R. Hansen2, K. Hughes1, U.Z. Ijaz3, C. Quince4, D. Gaya5, R. Russell2, K. Gerasimidis1
    1Human Nutrition, School of Medicine, College of Medical,
    Veterinary and Life Sciences, University of Glasgow, Glasgow Royal
    Infirmary, Glasgow, United Kingdom, 2Department of Paediatric
    Gastroenterology, Hepatology and Nutrition, Royal Hospital for
    Children, Glasgow, United Kingdom, 3School of Engineering,
    University of Glasgow, Glasgow, United Kingdom, 4Warwick
    Medical School, University of Warwick, Warwick, United Kingdom,
    5Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow,
    United Kingdom
      14:30-14:50 Future strategies to change the flora
    Harry Sokol, Paris, France
    14:50-15:20 Coffee break
    15:20-16:00 Scientific session 7: ECCO Fellowships and Grants
    Gerhard Rogler, Zurich, Switzerland
    Noortje Festen, Groningen, The Netherlands
      15:20-15:27 Outcomes from the 2015 Fellowships - Part 1
    Selective histone deacetylase inhibitors: A potentail new treatment of Imflammatory Bowels Disease
    Carla Felice, Rome, Italy
      15:27-15:34 Outcomes from the 2015 Fellowships - Part 2
    Sphingosine 1-phosphate (SIP)/S1PR3 axis a novel therapeutic target for intestinal fibrosis in Crohn's Disease

    Cristina Mascaraque, Granada, Spain
      15:34-15:40 Announcement of Fellowships and Grants 2016
    Gerhard Rogler, Zurich, Switzerland
      15:40-15:50 Best abstract: Efficacy and safety of oral tofacitinib as
    induction therapy in patients with moderate to severe Ulcerative
    Colitis: Results from two phase 3 randomised controlled trials
    W.J. Sandborn1, B.E. Sands2, G. D‘Haens3, S. Vermeire4, S. Schreiber5, S. Danese6, J. Panés7, B.G. Feagan8, W. Reinisch9, W. Niezychowski10, G. Friedman10, N. Lawendy10, D. Yu10, D. Woodworth10, A. Mukherjee11, P.
    Healey11, H. Zhang10, C. Su10
    1Division of Gastroenterology, University of California, San Diego,
    United States, 2Janowitz Division of Gastroenterology, Icahn School
    of Medicine at Mount Sinai, New York, United States, 3Academic
    Medical Centre, University of Amsterdam, Amsterdam, Netherlands,
    4Department of Gastroenterology, University Hospitals Leuven,
    Leuven, Belgium, 5Klinik für Innere Medizin I, Universitätsklinikum
    Schleswig-Holstein, Campus Kiel, Kiel, Germany, 6IBD Center,
    Department of Gastroenterology, Humanitas Research Hospital,
    Milan, Italy, 7Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd,
    Barcelona, Spain, 8Robarts Research Institute, London, Canada,
    9McMaster University, Hamilton, Canada, 10Pfizer Inc, Collegeville,
    United States, 11Pfizer Inc, Groton, United States
      15:50-16:00 Best abstract: Filgotinib, a selective JAK1 inhibitor, induces
    clinical remission in patients with moderate-to-severe Crohn’s
    Disease: Interim analysis from the phase 2 FITZROY study
    S. Vermeire
    1, S. Schreiber2, R. Petryka3, T. Kuehbacher4, X. Hebuterne5,
    X. Roblin6, M. Klopocka7, E. Goldis8, M. Wisniewska-Jarosinska9, A.
    Baranovsky10, R. Sike11, C. Tasset12, A. van der Aa12, P. Harrison12
    1UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, 2University
    Medical Center Schleswig-Holstein Kiel, Department of Internal
    Medicine I, Kiel, Germany, 3Vivamed, Warsaw, Poland, 4Asklepios
    Hospital West Hamburg, Department of Internal Medicine,
    Gastroenterology, Hamburg, Germany, 5Archet 2 Hospital,
    Department of Gastroenterology, Nice, France, 6Saint Etienne
    Hospital, Department of Gastroenterology, Saint Priest en
    Jarez, France, 7University Hospital Nr. 2 im. Biziela, Department
    of Gastroenterology, Bydgoszcz, Poland, 8Policlinica Algomed,
    Department of Gastroenterology, Timisoara, Romania, 9Saint Family
    Hospital Medical Center, Department of Gastroenterology and
    Endoscopy, Lodz, Poland, 10City Clinical Hospital #31, St Petersburg,
    Russian Federation, 11Szent Margit Hospital, Department of Internal
    Medicine and Gastroenterology III, Budapest, Hungary, 12Galapagos
    NV, Department of Development, Mechelen, Belgium
    16:00-17:00 Scientific session 8: Challenging Cases
    Peter Irving, London, United Kingdom
    Laurent Peyrin-Biroulet, Nancy, France
      16:00-16:20 Case 1: Challenges during pregnancy: Anti-TNF treatment during pregnancy
    Shannon Kanis, Rotterdam, The Netherlands 
      16:20-16:40 Case 2: Refractory upper gut Crohn's Disease: Refractory upper gut Crohn's disease with fatal outcome
    Miquel Cusachs, Barcelona, Spain  
      16:40-17:00 Case 3: When extra-intestinal symptoms dominate: Severe arthralgia in Crohn’s disease – disease  or drug-related?
    Donata Lissner, Berlin, Germany
    17:00-17:50 Scientific session 9: What's new on the Guidelines front?
    Oded Zmora, Tel Aviv, Israel
    Loris Lopetuso, Rome, Italy
      17:00-17:10 ECCO-ESCP Guidelines: Surgical Crohn's Disease
    Willem Bemelman, Amsterdam, The Netherlands
      17:10 - 17:20 Best abstract: Efficacy and safety of oral tofacitinib for
    induction therapy in patients with moderate to severe Crohn’s
    Disease: Results of a Phase 2b randomised placebo-controlled
    trial

    J. Panés
    1, W.J. Sandborn2, S. Schreiber3, B.E. Sands4, S. Vermeire5, G.
    Chan6, M. Moscariello6, W. Wang6, W. Niezychowski6, A. Marren6, P.
    Healey7, E. Maller6
    1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain,
    2Division of Gastroenterology, University of California, San Diego,
    United States, 3Klinik für Innere Medizin I, Universitätsklinikum
    Schleswig-Holstein, Campus Kiel, Kiel, Germany, 4Janowitz Division
    of Gastroenterology, Icahn School of Medicine at Mount Sinai, New
    York, United States, 5Deptartmentof Gastroenterology, University
    Hospitals Leuven, Leuven, Belgium, 6Pfizer Inc, Collegeville, United
    States, 7Pfizer Inc, Groton, United States
      17:20 - 17:30 ECCO Best abstract: Efficacy and safety of oral tofacitinib for
    maintenance therapy in patients with moderate to severe Crohn’s
    Disease: Results of a Phase 2b randomised placebo-controlled
    trial

    G. D‘Haens
    1, R. Pannaccione2, P.D.R. Higgins3, J.-F. Colombel3, B.G.
    Feagan4, M. Moscariello5, G. Chan5, P. Healey6, W. Niezychowski5, W.
    Wang5, A. Marren5, E. Maller5
    1Academic Medical Centre, University of Amsterdam, Amsterdam,
    Netherlands, 2University of Calgary, Calgary, Canada, 3University of
    Michigan, Ann Arbor, United States, 4Robarts Research Institute,
    London, Canada, 5Pfizer Inc, Collegeville, United States, 6Pfizer Inc,
    Groton, United States
      17:30-17:40 ECCO Guidelines: Ulcerative Colitis Update
    Rami Eliakim, Tel Hashomer, Israel
    Marcus Harbord, London, United Kingdom
      17:40-17:45 ECCO Topical Review: Fibrosis
    Florian Rieder, Cleveland, United States
      17:45-17:50 ECCO Topical Review: IBD in Elderly
    Paolo Gionchetti, Bologna, Italy
    18:05-19:05 Industry sponsored satellite symposia 4a & 4b 
    18:05-19:05 Digital oral presentations (Sessions 6-10)
  • Plenary hall

    07:15-08:15 Industry sponsored satellite symposia 5a & 5b 
    08:30-10:20 Scientific session 10: Surgical and Endoscopic FAQ's in IBD
    André D'Hoore, Leuven, Belgium
    Zuzana Serclova, Prague, Czech Republic
      08:30-08:50 Case 1 – Preparing your patient for optimal surgery
    Richard Fedorak, Edmonton, Canada
      08:50-09:00 Best abstract: Comparison between newly-developed NBI and
    panchromoendoscopy for surveillance colonoscopy in patients
    with Ulcerative Colitis: A prospective multicentre randomised
    controlled trial, Navigator Study
    K. Watanabe1, M. Nishishita2, F. Shimamoto3, T. Fukuchi4, M. Esaki5,
    Y. Okamoto5, Y. Maehata5, S. Oka6, S. Nishiyama6, S. Fujii7, F. Hirai8, T.
    Inoue9, N. Hida10, R. Nozaki11, T. Sakurai12, K. Takeuchi13, M. Saruta14, S.
    Saito15, Y. Saito16, N. Ohmiya17, H. Kashida12, S. Tanaka6, T. Matsui8, Y.
    Suzuki13, Y. Ajioka18, H. Tajiri19
    1Osaka City General Hospital, Gastroenterology, Osaka, Japan,
    2Nishishita Gastrointestinal Hospital, Osaka, Japan, 3Faculty of Human
    Culture and Science Prefectural University of Hiroshima, Hiroshima,
    Japan, 4Osakafu Saiseikai Nakatsu Hospital, Gastroenterology and
    Hepatology, Osaka, Japan, 5Graduate School of Medical Sciences,
    Kyushu University, Department of Medicine and Clinical Science,
    Fukuoka, Japan, 6Hiroshima University Hospital, Department
    of Endoscopy, Hiroshima, Japan, 7Kyoto Katsura Hospital,
    Digestive Disease Centre, Department of Gastroenterology,
    Kyoto, Japan, 8Fukuoka University Chikushi Hospital, Department
    of Gastroenterology, Fukuoka, Japan, 9Osaka Medical College,
    Second Department of Internal Medicine, Osaka, Japan, 10Hyogo
    College of Medicine, Department of Inflammatory Bowel Disease,
    Hyogo, Japan, 11Takano Hospital, Division of Gastroenterology,
    Coloproctology Center, Kumamoto, Japan, 12Kinki University,
    Department of Gastroenterology, Osaka, Japan, 13Toho University
    Sakura Medical Center, Department of Internal Medicine, Chiba,
    Japan, 14The Jikei University School of Medicine, Division of
    Gastroenterology and Hepatology, Department of Internal Medicine,
    Tokyo, Japan, 15The Jikei University School of Medicine, Department
    of Endoscopy, Tokyo, Japan, 16National Cancer Center Hospital,
    Endoscopy Division, Tokyo, Japan, 17School of Medicine, Fujita Health
    University, Department of Gastroenterology, Aichi, Japan, 18Graduate
    School of Medical and Dental Sciences, Niigata University, Division
    of Molecular and Diagnostic Pathology, Niigata, Japan, 19The Jikei
    University School of Medicine, Division of Gastroenterology and
    Hepatology, Department of Internal Medicine, Department of
    Endoscopy, Tokyo, Japan

      09:00-09:10 Best abstract: Mucosal healing and dysplasia surveillance in a
    large referral centre cohort of patients with Crohn’s Disease and
    Ulcerative Colitis treated with vedolizumab
    M. Noman1, M. Ferrante1, R. Bisschops1, G. De Hertogh2, K. van den
    Broeck1, K. Rans1, P. Rutgeerts1, S. Vermeire1, G. van Assche1
    1UZ Leuven, Gastroenterology, Leuven, Belgium, 2UZ Leuven,
    Campus Gasthuisberg, Pathology, Leuven, Belgium

      09:10-09:20 Best abstract: Escalation of medical therapy decreases need
    for repeat dilatation in Crohn‘s anastomatic strictures
    N.S. Ding1,2, W. Yip1, R. Choi1, B. Saunders3, S. Thomas-Gibson3, N.
    Arebi1, A. Humphries3, A. Hart1
    1St Mark‘s Hospital, IBD, London, United Kingdom, 2Imperial
    College London, Department of Surgery and Cancer, London,
    United Kingdom, 3St Mark‘s Hospital, Wolfson Unit For Endoscopy,
    Department of Gastroenterology, Harrow, United Kingdom

      09:20-09:40 Case 2 - Post-surgery prevention
    Marc Ferrante, Leuven, Belgium
      09:40-09:50 Best abstract: The TOPPIC trial: A randomised, double-blind
    parallel group trial of mercaptopurine vs placebo to prevent
    recurrence of Crohn’s Disease following surgical resection in 240
    patients
    I. Arnott1, C. Mowat2, H. Ennis3, C. Keerie3, S. Lewis3, N. Kennedy4, A.
    Cahill5, A. Morris5, M. Dunlop6, S. Bloom7, J. Lindsay8, S. Subramanian9,
    J. Satsangi4, on behalf of the Toppic Trial Study Group10
    1NHS Lothian, Gastroenterology, Edinburgh, United Kingdom,
    2NHS Tayside, Gastroenterology, Dundee, United Kingdom,
    3University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh,
    United Kingdom, 4University of Edinburgh, Gastroenterology,
    Edinburgh, United Kingdom, 5NHS Greater Glasgow and Clyde,
    Gastroenterology, Glasgow, United Kingdom, 6University of
    Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh,
    United Kingdom, 7University College Hospital, Department of
    Gastroenterology, London, United Kingdom, 8Bart‘s Health NHS
    Trust, Newham University Hospital, Department of Gastroenterology,
    London, United Kingdom, 9Royal Liverpool University Hospital,
    Gastroenterology, Liverpool, United Kingdom, 10Toppic Trial Study
    Group, UK, United Kingdom
      09:50-10:00 Best abstract: Anti-TNF therapy is associated with increased
    risk of postoperative morbidity after surgery for ileocolonic
    Crohn’s Disease: Outcome analysis in a prospective nationwide
    cohort of 592 patients conducted by the GETAID chirurgie group
    A. Brouquet1, L. Maggiori2, P. Zerbib3, J. Lefèvre4, Q. Denost5, A.
    Germain6, E. Cotte7, L. Beyer-Berjot8, N. Munoz-Bongrand9, V.
    Desfourneaux10, A. Rahili11, J.-P. Duffas12, K. Pautrat13, C. Denet14, V.
    Bridoux15, G. Meurette16, J.-L. Faucheron17, J. Loriau18, F. Guillon19, E.
    Vicaut20, S. Benoist1, Y. Panis2
    1Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive
    Surgery, Le Kremlin Bicêtre, France, 2Beajon Hospital, Colorectal
    Surgery, Clichy, France, 3CHU Lille, Digestive Surgery, Lille, France,
    4Saint Antoine Hospital, Digestive Surgery, Paris, France, 5CHU
    Bordeaux, Digestive Surgery, Bordeaux, France, 6CHU Nancy,
    Digestive Surgery, Nancy, France, 7CHU Lyon-Sud, Digestive Surgery,
    Lyon, France, 8CHU Marseille, Digestive Surgery, Marseille, France,
    9Saint Louis Hospital, Digestive Surgery, Paris, France, 10CHU Rennes,
    Digestive Surgery, Rennes, France, 11CHU Nice, Digestive Surgery,
    Nice, France, 12CHU Toulouse, Digestive Surgery, Toulouse, France,
    13Lariboisière Hospital, Digestive Surgery, Paris, France, 14Montsouris
    Institute, Digestive Surgery, Paris, France, 15CHU Rouen, Digestive
    Surgery, Rouen, France, 16CHU Nantes, Digestive Surgery, Nantes,
    France, 17CHU Grenoble, Digestive Surgery, Grenoble, France, 18Saint-
    Joseph Hospital, Digestive Surgery, Paris, France, 19CHU Montpellier,
    Digestive Surgery, Montpellier, France, 20Fernand Widal Hospital,
    Clinical Research, Paris, France
      10:00-10:20 Case 3 - Dealing with a problematic pouch
    Michael Kamm, Melbourne, Australia
    10:20-10:50 Coffee break
    10:50-12:20 Scientific session 11: Right time, right drug, right strategy
    Marieke Pierik, Maastricht, The Netherlands
    Nik Ding, London, United Kingdom
      10:50-11:10 Molecular stratification of the patient
    Miles Parkes, Cambridge, United Kingdom
      11:10-11:20 Best abstract: Pharmacokinetics and exposure-response
    relationships of intravenously administered ustekinumab during
    induction treatment in patients with Crohn’s Disease: Results from
    the UNITI-1 and UNITI-2 studies
    O.J. Adedokun1, Z. Xu1, C. Gasink1, J. Friedman1, P. Szapary1, Y. Lang1,
    J. Johanns1, L.-L. Gao1, Y. Miao1, H. Davis1, S. Hanauer2, B. Feagan3, W.
    Sandborn4
    1Janssen R & D, LLC, Spring House, United States, 2Northwestern
    University Feinberg School of Medicine, Chicago, United States,
    3Robarts Clinical Trials Inc., Robarts Research Institute, University of
    Western Ontario, London, Canada, 4UCSD, Medicine, La Jolla, United
    States
      11:20-11:40 Choosing the right drug
    Iris Dotan, Tel Aviv, Israel
      11:40-11:50 Best abstract: Drug-concentration versus symptom-driven
    dose adaptation of infliximab in patients with active Crohn’s
    Disease: A prospective, randomised, multicentre trial (Tailorix)
    G. D´Haens
    1, S. Vermeire2, G. Lambrecht3, F. Baert4, P. Bossuyt5, M.
    Nachury6, A. Buisson7, Y. Bouhnik8, J. Filippi9, J. van der Woude10, P. van
    Hootegem11, J. Moreau12, E. Louis13, D. Franchimont14, M. De Vos15,
    F. Mana16, L. Peyrin-Biroulet17, H. Brixi18, M. Allez19, P. Caenepeel20,
    A. Aubourg21, B. Oldenburg22, M. Pierik23, A. Gils24, S. Chevret25, D.
    Laharie26
    1Academic Medical Centre, Gastroenterology, Amsterdam, Netherlands,
    2University Hospitals Gasthuisberg, Gastroenterology, Leuven,
    Belgium, 3AZ Damiaan, Oostende, Belgium, 4AZ Delta, Roeselare,
    Belgium, 5Imelda GI Clinical Research Centre, Bonheiden, Belgium,
    6Hopital Claude Hurriez, Lille, France, 7Hopital Estaing, Clermont-
    Ferrand, France, 8Hopital Beaujon, Clichy, France, 9Hospital Archet,
    Nice, France, 10Erasmus Medical Centre, Rotter-dam, Netherlands, 11St
    Lukas Hospital, Bruges, Belgium, 12Hopital Rangueil, Toulouse, France,
    13Hopital Sart Tilman, Liège, Belgium, 14Hopital Erasme, Brussels,
    Belgium, 15University of Ghent, Ghent, Belgium, 16Free University of
    Brussels, Brussels, Belgium, 17Hopital Brabois, Nancy, France, 18Hopital
    Robert Debre, Reims, France, 19Hopital St Louis, Paris, France,
    20Ziekenhuis Oost Limburg, Genk, Belgium, 21Hopital Trousseau,
    Tours, France, 22University of Utrecht, Utrecht, Netherlands,
    23University Hospital Maastricht, Maastricht, Netherlands, 24University
    of Leuven, Leuven, Belgium, 25Department Biostatistique St Louis,
    Paris, France, 26Haut-Leveque, Pessac, France
      11:50-12:00 Best abstract: Factors associated with the first trough level of
    infliximab at week 2 that predicts short- and long-term outcomes
    in Ulcerative Colitis
    T. Kobayashi
    1, Y. Suzuki2, S. Motoya3, F. Hirai4, H. Ogata5, H. Ito6, N.
    Sato7, K. Ozaki7, M. Watanabe8, T. Hibi1
    1Kitasato University Kitasato Institute Hospital, Center for Advanced
    IBD Research and Treatment, Tokyo, Japan, 2Toho University
    Sakura Medical Center, Department of Internal Medicine, Sakura,
    Japan, 3Sapporo-kosei General Hospital, Inflammatory Bowel
    Diseases Center, Sapporo, Japan, 4Fukuoka University Chikushi
    Hospital, Department of Gastroenterology, Chikushino, Japan,
    5Keio University School of Medicine, Center for Diagnostic and
    Therapeutic Endoscopy, Tokyo, Japan, 6Kitano Hospital The Tazuke
    Kofukai Medical Research Institute, Digestive Disease Center, Osaka,
    Japan, 7Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 8Tokyo
    Medical and Dental University, Department of Gastroenterology and
    Hepatology, Tokyo, Japan
      12:00-12:20 Care or action plans for patients
    Jane Andrews, Adelaide, Australia
    Karen Kemp, Manchester, United Kingdom
    12:20-12:50 Scientific session 12: ECCO Lecture
    Séverine Vermeire, Leuven, Belgium
    Julián Panés, Barcelona, Spain
      12:20-12:50 Future of IBD healthcare in Europe
    Daniel Hommes, Los Angeles, United States
    12:50-12:55 Awards and closing remarks
    Julián Panés, Barcelona, Spain
    12:55-13:00
    The ECCO Film 2016